Dupixent For Moderate-To-Severe Asthma Treatment Market Expected To Reach ~$8.1 Billion By 2032. December 13, 2025 7:27 am - The Dupixent market for moderate-to-severe asthma is valued at $3.25 ...

Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in ...

A few months after Sanofi and Regeneron’s Dupixent scored a new indication as the first and only medicine to treat eosinophilic esophagitis (EoE) in patients 12 and older, new late-stage trial data ...

Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

This year has been one for the books in medicine. From Ozempic’s expanded role in protecting failing kidneys to long‑acting ...

Dupixent is a blockbuster immunology drug that just keeps delivering for Sanofi and Regeneron, so it’s no surprise that the “franchise in a therapy” has got a new set of ads. Sanofi and Regeneron, ...

First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved ...

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

TRENTON, N.J. --U.S. regulators have approved the first powerful, injected medicine to treat serious cases of the skin condition eczema. The Food and Drug Administration on Tuesday approved Dupixent ...